Five things for pharma marketers to know: Friday, August 25, 2017
1. If you search for “clinical depression” on Google, you may be invited to take a questionnaire to see if you're depressed. The test is a part of a Google partnership with the National Alliance of Mental Illness. (CNBC)
2. Patients with diabetes that adhered to their treatment regimen had 235 fewer ER visits and 50 fewer inpatient hospitalizations per 1000 patients in 2016, according to Express Scripts.
3. Imraldi, a biosimilar version of AbbVie's Humira, that is manufactured by Biogen and Samsung Biologics, received approval in the European Union. Samsung has also received approval to market biosimilars of Amgen's Enbrel and Johnson & Johnson's Remicade in the European Union, as well. (Reuters)
4. Novartis acquired an experimental drug for Behcet's disease from Xoma for $31 million. The drug, gevokizumab, failed a Phase-III trial two years ago. (Endpoints News)
5. Every county in the U.S. now has at least one insurer selling health plans on an Obamacare exchange. Republicans have frequently criticized the Affordable Care Act, saying insurers were pulling out of exchanges and that they would implode. (NYT)